Pharmacologic treatment of bladder hyperactivity after augmentation and substitution enterocystoplasty.
Department of Clinical Pharmacology, University Hospital, Lund, Sweden.
K E
KE
Andersson
H
H
Hedlund
W
W
Månsson
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D011183:Postoperative Complications / Q000188:drug therapy*; D011976:Receptors, Muscarinic / Q000187:drug effects*; D011957:Receptors, Opioid / Q000187:drug effects*; D001743:Urinary Bladder / Q000187:drug effects* / Q000601:surgery; D016476:Urinary Reservoirs, Continent
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D011976:Receptors, Muscarinic; D011957:Receptors, Opioid